The story of Sildenafil presents a interesting case for stakeholders in the drug sector. While initially a tremendous success, generating vast sums, the exclusivity lapse and the subsequent entry of off-brand versions https://porn209747.blogdigy.com/the-little-copyright-and-pharma-a-risky-bet-67474263